biotech · Acute Myeloid Leukemia · Sarcoma,Soft Tissue · MBRX
Moleculin Biotech
Moleculin Biotech is a biotech organization headquartered in Houston, USA. It trades on NYSE under ticker MBRX. Primary therapeutic focus areas include Acute Myeloid Leukemia, Sarcoma,Soft Tissue, Leukemia, Myeloid, Acut
Houston, USA HQ
2006 Founded
22 Employees
Public company Type
MBRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Houston, USA
- Founded
- 2006
- Employees
- 22
- Programs
- 9
- Drugs
- 10
- Patents
- 1
STAT3 Inhibitor WP1066
Phase 2 · small molecule · Glioblastoma, IDH-Wildtype
STAT3 Inhibitor WP1066 for Glioblastoma, IDH-Wildtype is a Phase 2 program (small_molecule) at Moleculin Biotech with 1 ClinicalTrials.gov record(s).
Internal code NU 21C06
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Moleculin Biotech
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Glioblastoma, IDH-Wildtype
- Status
- active
- Trials
- 1